Therefore, it can be hypothesized that the MAPK signaling pathway might act as a pivotal downstream (rather than upstream) signaling pathway for SLC34A2 and SLC4A4, to promote the tumor progression of PTCs. Here, SLC4A4 is linked to neoplasm.